In 2018, President Trump signed the Right to Try Act — legislation that gave terminally ill patients the legal right to access experimental treatments outside of the FDA approval process. It was celebrated as a historic step toward medical freedom. But for millions of Americans seeking access to safe, off-patent, generic medications that their doctors are willing to prescribe, it changed very little.
The real battle for medical freedom is not about experimental treatments. It is about established, safe, inexpensive medications that have been used successfully for decades — and the systematic effort to make them inaccessible whenever they compete with profitable pharmaceutical products.
The Pattern Is Clear
Consider the trajectory of several medications: ivermectin (Nobel Prize, 40-year safety record, billions of doses), hydroxychloroquine (65 years on the market, lupus and RA mainstay), fenbendazole (widely used antiparasitic, growing cancer research), mebendazole (50-year safety profile, documented anti-cancer activity). Each of these medications became the target of regulatory and media suppression at precisely the moment when they began competing with expensive pharmaceutical products.
This is not a coincidence. It is the predictable behavior of an industry that spends more on lobbying than on research, and that has successfully captured the regulatory agencies that are supposed to hold it accountable.
The Constitutional Dimension
The 9th and 10th Amendments to the Constitution reserve to individuals and states all powers not explicitly granted to the federal government. The power to restrict a patient's access to a medication their physician has prescribed does not appear anywhere in the Constitution. It was claimed by regulatory agencies whose authority has expanded far beyond anything the founders contemplated — or that voters ever explicitly approved.
Conservatives and libertarians have long argued that the FDA's drug approval monopoly creates as many problems as it solves. When the cost of bringing a drug to market exceeds $1 billion, only pharmaceutical companies with massive capital can afford to do it — and they will only pursue drugs that can be patented. Every cheap generic with potential therapeutic value is effectively locked out of legitimate clinical development. The human cost of this structural failure is incalculable.
What You Can Do
Medical freedom begins with information. Read the research. Understand the mechanisms. Talk to physicians who practice integrative or functional medicine and who are willing to engage with the full landscape of therapeutic options — not just the ones that insurance will reimburse.
Access to medications like ivermectin, fenbendazole, HCQ, and others is a matter of individual sovereignty. You have the right to make decisions about your own body with your physician's guidance. The infrastructure to support that right — from telemedicine providers willing to prescribe off-label to pharmacies that will fill those prescriptions — exists and is growing.
The Stakes
The COVID-19 pandemic revealed, in sharp relief, the consequences of concentrated medical authority. Tens of thousands of physicians who dissented from official guidance were threatened with license revocation. Patients who wanted early treatment were turned away. A 65-year-old drug was relabeled dangerous for political reasons.
If that does not motivate a renewed commitment to medical freedom, it is hard to imagine what would.
Key Takeaway: Medical freedom — the right of patients and physicians to make treatment decisions without bureaucratic interference — has never been more important, and access to proven, safe, off-patent medications is its most immediate and concrete expression.